Déficit cognitivo en la esquizofrenia, una revisión bibliográfica
Dr. Daniel
Dr. Daniel Sotelo, Dra. Romina Capellino, Dra. María José Flores Moure, Dra. Verónica Grasso of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 2003 Feb 1;59(2- 3):137-46. • 25. Harvey PD, Reichenberg A, Bowie CR, Patterson TL, Heaton RK. The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay. Biol Psychiatry 2010, 15;67(10):933-9. • 26. Hedman AM, Van Haren NE, Van Baal CG, Kahn RS, Hulshoff P. IQ change over time in schizophrenia and healthy individuals: a meta-analysis. Schizophr Res. 2013 May;146(1- 3):201-8. • 27. Mathes B, Wood SJ, Proffitt TM, Stuart GW, Buchanan JA, Velakoulis D, et al. Early processing deficits in object working memory in first-episode schizophreniform psychosis and established schizophrenia. Psychol Med. 2005;35(7):1053-62. • 28. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31:5–21. • 29. Krabbendam L, ArtsB, Van Os J, Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. SchizophrRes.2005;80(2-3):137-149. • 30. Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: A comparison of patients with various first-episode psychosis presentations .AmJ Psychiatry.2010;167(1):78-85. • 31. Harvey PD, Docherty NM, Serper MR, Rasmussen M. Cognitive deficits and thought disorder: II. An 8-month followup study.Schizophr Bull. 1990;16:147–156. • 32. Albus M, Hubmann W, Wahlheim C, Sobizack N, Franz U, Mohr F. Contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first episode affective disorders. ActaPsychiatr Scand. 1996;94: 87–93. • 33. Gale CR, Batty GD, McIntosh AM, Porteous DJ, Deary IKJ, Rasmussen F. Is bipolar disorder more common in highly intelligent people? A cohort study of a million men. Mol Psychiatry.2012;18(2): 190-194. • 34. MacCabe JH, Lambe MP, Cnattingius S, et al. Excellent school performance at age16 and risk of adult bipolar disorder: national cohort study. BrJ Psychiatry.2010;196(2):109-115 • 35. Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorders. Neuropsychiatry NeuropsycholBehav Neurol. 1998;11: 111–119. • 36. van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. Arch Gen Psychiatry. 1998;55:41–46. • 37. Keefe RSE, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033–2046. • 38. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 25 year follow-up study. Schizophr Res. 2000;44:47–56. • 39. Strauss ME. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull. 1993;19:215–231. • 40. Bonilha L, Molnar C, Horner MD, Anderson B, Forster L, George MS, Nahas Z.Neurocognitive deficits and prefrontal cortical atrophy in patients with schizophrenia.Schizophr Res. 2008,142-51. • 41. Keefe R, Eesley C. Deficits Neurocognitivos en Tratado de esquizofrenia, Liberman J, Scott Stroup, T, Perkins, D, Ars Medica 2008 243-258. • 42. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’? Schizophr Bull. 2000;26:119–136. • 43. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.Am J Psychiatry. 2005 Mar;162(3):495-506. • 44. Fu S, Czajkowski N, Rund BR, Torgalsbøen AK. The relationship between level of cognitive impairments and functional outcome trajectories in first-episode schizophrenia.Schizophr Res. 2017 Dec;190:144-149. • 45. Green MF, Harvey PD Cognition in schizophrenia: Past, present, and future.Schizophr Res Cogn. 2014 Mar;1(1):e1-e9. • 46. Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull.2007;33(4):912-920. • 47. Morris Bell H, Tsang H, Tamasine C. Bryson G, Greig. Neurocognition, Social Cognition, Perceived Social Discomfort, and Vocational Outcomes in Schizophrenia, Schizophr Bull. 2009 Jul; 35(4): 738–747. • 48. De Erausquin G,, Mecanismo de acción molecular de los antipsicóticos Vertex. 2003 Mar-May;14(51):36-44. • 49. Green M, Katiah Llerena R. Kern R. The “Right Stuff” Revisited: What Have We Learned About the Determinants of Daily Functioning in Schizophrenia? Schizophrenia Bulletin 2015 (41) 781–785. • 50. Walker A, Spring J, Travis M,.Addressing Cognitive Deficits in Schizophrenia: Toward a Neurobiologically Informed Approach. Biol Psychiatry. 2017; 81(1): e1 e3. • 51. Yang YS, Marder SR, Green MF. Repurposing Drugs for Cognition in Schizophrenia. ClinPharmacolTher. 2017 Feb;101(2):191-193. • 52. Bumb, J. M., Enning, F, Leweke, F. M. Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert OpinPharmacother 2015 16, 1049–1067. • 53. Young, J. W, Geyer, M. A. Biochemical Pharmacology. BiochemicalPharmacology 2013, 86, 1122–1132. • 54. de Leon J, Susce MT, Diaz FJ, Rendon DM, Velásquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry. 2005 Nov;66(11):1447-55. • 55. Kumari V, Aasen I, ffytche D, Williams SC, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage. 2006 29(2):545-56. • 56. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. BiochemPharmacol. 2013 Oct 15;86(8):1122-32. • 57. Bumb, J. M., Enning, F. Leweke, F. Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother 2015 16, 1049–1067. • 58. Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D’Souza DC. Going up in smoke?A review of nAChRsbased treatment strategies for improving cognition in schizophrenia, Curr Pharm Des. 2014;20. • 59. Arnsten AFT, Girgis RR, Gray DL, Mailman RB. Novel dopamine therapeutics for cognitive deficits in schizophrenia. BiolPsychiatry. 2017;81:67–77. 10 // EDITORIAL SCIENS
